? The intersection of federal tax policy and cannabis business economics presents a nuanced challenge for clinicians advocating for patients in states where cannabis is legal. While the potential removal or modification of Internal Revenue Code Section 280E (which prohibits cannabis businesses from deducting ordinary business expenses) could theoretically improve product affordability and accessibility, concurrent tariff policies may offset these gains by increasing operational costs for cultivators and retailers. Healthcare providers should recognize that cannabis pricing and availability in their communities are shaped by complex fiscal policies beyond clinical considerations, and that patients’ out-of-pocket costs may remain elevated regardless of tax or tariff changes. When counseling patients about cannabis use for symptom management, clinicians should remain attuned to cost barriers that may influence adherence or drive patients toward unregulated products, while advocating for transparent information about how regulatory and fiscal environments affect the legal cannabis market they’re recommending.